{"entity":{"id":"tnbc-molecular-subtyping","kind":"term","name":"TNBC molecular subtyping","aka":["TNBCtype","TNBCtype-4","Lehmann subtypes","TNBC expression subtypes"],"tldr":"TNBC RNA subtyping compares gene-expression patterns under a named research classifier. Tissue mixture, method and version matter, and the result is separate from receptor tests or a treatment choice.","summary":"Lehmann's original TNBCtype system described six expression groups: BL1, BL2, IM, M, MSL and LAR. The 2016 TNBCtype-4 refinement retained BL1, BL2, M and LAR as tumour-focused profiles after evaluating immune and stromal contributions to the IM and MSL signals. Removed-profile samples were reassigned to their second-highest correlated tumour-profile centroid, not automatically to M.\n\nBL1 is associated with cell-cycle/DNA-damage-response programmes; BL2 with growth-factor and myoepithelial-associated expression; M with motility and differentiation; and LAR with luminal and androgen-related transcription. These are classifier associations, not proof of one cause, functional repair deficiency or dependence on an inhibitor.","asOf":"2026-11-09","links":[{"label":"Lehmann 2011: original expression profiles and cell-model experiments","url":"https://pubmed.ncbi.nlm.nih.gov/21633166/"},{"label":"Lehmann 2016: tissue attribution and TNBCtype-4 refinement","url":"https://pubmed.ncbi.nlm.nih.gov/27310713/"},{"label":"Chen 2012: TNBCtype input and reported correlation/permutation statistics","url":"https://pubmed.ncbi.nlm.nih.gov/22872785/"},{"label":"Zhao 2020: specified Fudan research IHC classifier","url":"https://pubmed.ncbi.nlm.nih.gov/32406563/"},{"label":"FUTURE-SUPER primary randomised phase 2 report","url":"https://pubmed.ncbi.nlm.nih.gov/38211606/"}],"tags":["education-audit","classification"],"related":["pam50","basal-like","luminal-androgen-receptor","future-super"],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-lehmann-tnbc-subtypes-jci-2011","paper-lehmann-tnbctype-4-refinement-plos-one-2016","paper-future-super-lancet-oncology-2024"],"journals":[],"dependsOn":[],"notes":["Record tissue identity, timing relative to treatment, tumour content, RNA qualification, platform, gene coverage, preprocessing, normalisation, reference data, classifier/version and competing correlations. A reported correlation or permutation p-value is not automatically a probability. No universal RNA-quality cutoff qualifies every platform.","A mixed-tissue IM signal and a BL1 call from an enriched preparation can coexist without proving tumour evolution. Compare preparation, method and scores. Tumour-focused labels do not make every bulk input free of immune or stromal RNA.","PAM50 basal-like, AR protein positivity, an RNA LAR label, histology and receptor-defined TNBC are separate measurements. A lineage-associated programme does not establish an exact cell of origin.","The defining cell-model and retrospective chemotherapy studies generated treatment hypotheses. Prospective strategy research also exists: FUTURE-SUPER used a distinct Fudan classifier plus genomic biomarkers and compared matched regimens with nab-paclitaxel alone. Its pooled phase 2 result does not validate every same-named profile or isolate the value of a classifier from its treatment bundle."],"category":"Cancer biology"},"route":"/terms/tnbc-molecular-subtyping/","neighbours":{"term":[{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/"},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/"},{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/"}],"trial":[{"id":"future-super","kind":"trial","name":"FUTURE-SUPER","route":"/trials/future-super/"}],"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"paper":[{"id":"paper-future-super-lancet-oncology-2024","kind":"paper","name":"FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC","route":"/key-papers/paper-future-super-lancet-oncology-2024/"},{"id":"paper-lehmann-tnbc-subtypes-jci-2011","kind":"paper","name":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","route":"/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/"},{"id":"paper-lehmann-tnbctype-4-refinement-plos-one-2016","kind":"paper","name":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","route":"/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/"}]}}